Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.00 – $0.00
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $140.2M | $151.5M | $127.3M | $105.6M | $125.1M | $158.3M | $169.5M | $90.4M |
| Cost of revenue | $77.8M | $77.4M | $61.3M | $50.6M | $59.5M | $75.1M | $82.7M | $46.4M |
| Gross profit | $62.4M | $74.0M | $66.0M | $55.0M | $65.6M | $83.9M | $86.8M | $43.9M |
| Gross margin | 44.5% | 48.9% | 51.8% | 52.1% | 52.4% | 53.0% | 51.2% | 48.6% |
| R&D | $13.1M | $12.0M | $12.8M | $7.3M | $7.7M | $8.8M | $6.1M | $2.4M |
| Operating income | −$7.7M | −$9.1M | −$61.3M | −$10.9M | −$5.4M | −$6.2M | −$5.3M | −$35.5M |
| EBITDA | $11.6M | $18.8M | $30.9M | $14.3M | $23.4M | $20.5M | $10.8M | $11.0M |
| Net income | −$7.4M | −$5.0M | −$83.9M | −$32.9M | −$12.9M | −$32.1M | −$23.1M | −$39.5M |
| Net margin | -5.3% | -3.3% | -65.9% | -31.2% | -10.3% | -20.3% | -13.7% | -43.7% |
| EPS (diluted) | -0.01 | -0.01 | -0.15 | -0.05 | -0.02 | -0.05 | -0.02 | -0.05 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $84M | $0.01 | $0.01–$0.01 | 1 |
| 2027 | $90M | $0.01 | $0.01–$0.01 | 1 |
Forward consensus · source: Financial Modeling Prep
BENCHMARK HLDGS PLC
No one on the platform currently holds BHCCF.
No tracked institution reports a position in BHCCF as of their last filing.
No one on the platform has traded BHCCF yet.
| +0.00% |
| $2M |
| — |
| MAYNFMayne Pharma Group Limited | $1.65 | +0.00% | $134M | — |
| ORPEFOrpea S.A. | $14.22 | +0.00% | $2.3B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.